CD8A and neoplasm: Notably, in pre-clinical models, T-VEC was synergistic with anti-CTLA-4 (cytotoxic T-lymphocyte antigen 4) ICB therapy, resulting in an increase in tumor-specific CD3+ and CD8+ T cells [95,96].